Some liver concerns, but FDA mostly favorable on Durata's dalbavancin
This article was originally published in Scrip
Executive Summary
Other than some liver concerns, which weren't drastic, and the reports of adverse hemorrhage events, the FDA gave Durata Therapeutics' experimental antibiotic a positive review, declaring the drug has an overall favorable safety profile with similar rates of mortality and non-fatal side effects as its study comparators.